Huaren Pharmaceutical(SZ:300110) Xin Lang Cai Jing·2025-11-18 01:26Core Insights - Huarun Pharmaceutical's stock price remained unchanged on November 17, with a trading volume of 79.44 million yuan [1] - The company experienced a net financing outflow of 2.29 million yuan on the same day, indicating a decrease in investor confidence [1][2] - The company's revenue for the first nine months of 2025 was 976 million yuan, a year-on-year decrease of 9.07%, while net profit dropped by 42.87% to 54.58 million yuan [2] Financing and Margin Trading - On November 17, Huarun Pharmaceutical had a financing buy-in of 4.08 million yuan, with a total financing balance of 234 million yuan, accounting for 5.46% of its market capitalization [1] - The financing balance is below the 50th percentile level over the past year, indicating a relatively low level of leverage [1] - The company had no short selling activity on November 17, with a short selling balance of 0, which is above the 70th percentile level over the past year, suggesting a high level of short selling interest [1] Shareholder Information - As of November 10, the number of shareholders for Huarun Pharmaceutical was 40,100, a decrease of 1.23% from the previous period [2] - The average number of circulating shares per shareholder increased by 1.25% to 29,447 shares [2] Dividend Distribution - Since its A-share listing, Huarun Pharmaceutical has distributed a total of 294 million yuan in dividends, with 49.65 million yuan distributed over the past three years [3]